Print

Merck & Co., Inc. (MRK) Release: VICTRELIS® (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent  
10/17/2012 9:57:18 AM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that VICTRELIS® (boceprevir) 200 mg Capsules, the company’s oral treatment for chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin has received the Prix Galien USA Award for Best Pharmaceutical Agent.
//-->